Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial

5-Lipoxygenase Metabolic Contributions to NSAID-Induced Organ Toxicity

“…Six-month, well-controlled trials of celecoxib against traditional NSAIDs have shown this selective COX-2 inhibitor to be GI sparing [17,18]. In an analysis by the US Food and Drug Administration (FDA), however, follow-up of subjects in the Celecoxib Longterm Arthritis Safety Study (CLASS) trial for an additional 6 months after the trial ended showed that when total ulcer complications were considered, according to the pre-specified criteria in the trial protocol, there was no appreciable difference in cumulative percentage between celecoxib and traditional NSAIDs [19,20].…”

Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Part II

“…Целекоксиб реже вызывает осложнения у пациентов с ФР ЖКТ-осложнений, чем н-НПВП в сочетании с инги-битором протонной помпы (ИПП), что было доказано в РКИ CONDOR [149]. В ходе этого исследования 4481 больной РА или ОА с язвенным анамнезом или возрастом >60 лет, не инфицированные H. pylori, в течение 6 мес принимали целекоксиб 400 мг или диклофенак 150 мг в сутки + омепразол 20 мг.…”

Gastrointestinal Events in Rheumatoid Arthritis: Time for the Lower Gastrointestinal Tract!

“…However, the efficacy of PPI in the lower GI tract is not known, and current literature is contradictory; from a theoretical point of view PPI might not work in the lower GI tract 8 , whereas animal models contradict each other: one suggests exacerbation of small intestinal lesions by inducing dysbiosis 9 , whereas another suggests prevention of NSAID-induced small-intestine lesions 10 . A first clinical answer comes from the CONDOR study 11 . In this 6-month randomized double-blind trial almost 4500 patients with RA or osteoarthritis were treated with either celecoxib twice daily 200 mg or diclofenac twice daily 75 mg in combination with omeprazole.…”